Annotation Detail
Information
- Associated Genes
- ABL1
- Associated Variants
- ABL1 p.Phe505Ser (p.F505S) ABL1 p.Phe505Ser (p.F505S)
- Associated Disease
- chronic myeloid leukemia
- Source Database
- CIViC Evidence
- Description
- In an in vitro study, a Ba/F3 cell line stably expressing the F486S mutation in the ABL1 portion of the BCR-ABL1 fusion protein was associated with sensitivity to nilotinib treatment (IC50: 1.85-fold), comparable to Ba/F3 cells expressing BCR-ABL fusion protein. Sensitivity was determined by assessing cell proliferation.
- Variant Origin
- somatic
- Variant Origin
- Somatic
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/2829
- Gene URL
- https://civic.genome.wustl.edu/links/genes/4
- Variant URL
- https://civic.genome.wustl.edu/links/variants/1152
- Rating
- 3
- Evidence Type
- Predictive
- Disease
- Chronic Myeloid Leukemia
- Evidence Direction
- Supports
- Drug
- Nilotinib
- Evidence Level
- D
- Clinical Significance
- Sensitivity/Response
- Pubmed
- 19075254
Drugs
| Drug Name | Sensitivity | Supported |
|---|---|---|
| Nilotinib | Sensitivity | true |